We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Avenue

News List

Avenue Therapeutics gets complete response letter from USFDA for IV Tramadol expresspharma
June 16, 2021
Avenue Therapeutics, focused on the development of intravenous (IV) tramadol for the US market, announced that it has received a second Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) regarding its New Drug Application ...
Avenue Therapeutics Announces NDA Submission for IV Tramadol americanpharmaceuticalreview
December 17, 2019
Avenue Therapeutics has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for IV tramadol for the management of moderate to ...
Avenue Announces Positive Phase 3 Trial Results contractpharma
May 22, 2018
Avenue Therapeutics announced that its first pivotal Phase 3 trial of IV tramadol achieved the primary endpoint of a statistically significant improvement